Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Viralym-M Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant Read more
A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Sickle Cell Disease Read more
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Relatlimab and Nivolumab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma Read more
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas Read more
A Phase 2 Study Of The Safety and Tolerability of Sargramostim Added To Standard Of Care Ipilimumab Containing Checkpoint Inhibitor Therapy In Patients With Solid Tumors Read more
A two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment with Nivolumab in Patients with Advanced Solid Malignancies. Read more
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) Read more
An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of Ro7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors. Read more
